Engerix-B 10MCG Pediatric Hep B Vaccine at Chughtai Lab

Engerix-B 10MCG (Hep B Child) 0.5ml Vial at Chughtai Lab

Engerix-B 10MCG (Hep B Child) 0.5ml Vial is a sterile, non-infectious recombinant DNA vaccine used to immunize infants, children, and adolescents against infection caused by the Hepatitis B virus (HBV). Hepatitis B is a serious viral infection that targets the liver, potentially leading to acute illness, chronic liver disease, cirrhosis, and hepatocellular carcinoma (liver cancer). The vaccine contains purified hepatitis B surface antigen (HBsAg) produced by genetically engineered yeast cells (Saccharomyces cerevisiae) adsorbed onto aluminum hydroxide as an adjuvant to enhance the immune response. Administering this vaccine at Chughtai Lab, a premier diagnostic and preventive healthcare provider in Pakistan, ensures that your child receives a highly potent, properly stored, and professionally administered vaccine. Immunization is the most effective clinical strategy to prevent the transmission of Hepatitis B, especially in regions like Pakistan where the virus remains endemic. By choosing Chughtai Lab, parents can be assured of strict adherence to international cold chain protocols, sterile administration techniques, and comprehensive documentation of their child’s immunization schedule.

The Engerix-B pediatric vaccine works by stimulating the child’s immune system to produce specific antibodies (anti-HBs) against the hepatitis B surface antigen. When the body is exposed to these non-infectious viral proteins, helper T-cells and B-cells are activated, establishing a robust immunological memory. If the child is exposed to the actual Hepatitis B virus in the future, the immune system rapidly recognizes the surface antigen and deploys neutralizing antibodies to eliminate the virus before it can infect hepatic cells. This proactive defense mechanism provides long-term, often lifelong, protection against all known subtypes of the Hepatitis B virus. The clinical value of this immunization cannot be overstated, as preventing childhood HBV infection drastically reduces the risk of developing chronic carrier status, which affects up to 90% of infected infants compared to only 5% to 10% of individuals infected during adulthood.

Clinical Procedure: What to Expect

Patient Preparation

Preparing a child for the Engerix-B 10MCG vaccination at Chughtai Lab involves simple but critical clinical steps to ensure safety and comfort. Parents should observe the following guidelines:

• Medical History Disclosure: Inform the healthcare provider of any known allergies, particularly severe hypersensitivity to yeast or any previous dose of a Hepatitis B vaccine.
• Current Health Status: Disclose if the child is currently suffering from a moderate or severe acute illness, with or without fever. Mild illnesses, such as a common cold or low-grade fever, are generally not contraindications for vaccination.
• Bleeding Disorders: Inform the staff if the child has a bleeding disorder, such as hemophilia, or is taking blood thinners, as this requires special care during intramuscular injection to prevent hematoma.
• Comfortable Clothing: Dress the child in loose, comfortable clothing that allows easy access to the injection site. For infants, the thigh is the preferred site, while the upper arm (deltoid) is used for older children.
• Calming the Child: Parents are encouraged to comfort, hold, or distract the child during the procedure to minimize movement and anxiety.

During the Procedure

The administration of the Engerix-B 10MCG vaccine at Chughtai Lab follows strict clinical standards to guarantee safety and efficacy:

• Verification and Inspection: The trained nurse or healthcare professional verifies the vaccine name, dosage (0.5ml), expiration date, and visual appearance of the suspension. The vial is shaken well to obtain a slightly opaque, white suspension.
• Patient Positioning: Infants and toddlers are securely held by their parents on their lap, exposing the anterolateral aspect of the thigh. Older children sit upright, exposing the deltoid muscle of the non-dominant arm.
• Aseptic Technique: The injection site is thoroughly cleansed with an alcohol swab and allowed to air dry completely.
• Intramuscular Injection: The vaccine is administered strictly via intramuscular (IM) injection at a 90-degree angle. Subcutaneous or intradermal administration is avoided as it may result in a suboptimal immune response.
• Disposal and Documentation: The syringe is immediately disposed of in a designated sharps container. The vaccination card is updated with the batch number, manufacturer, date of administration, and next scheduled dose.
• Post-Vaccination Observation: The child is observed in the clinic for 15 to 20 minutes post-injection to monitor for any immediate allergic reactions or syncope (fainting).

When is Engerix-B 10MCG (Hep B Child) Performed?

Routine Infant Immunization Schedule

The primary clinical indication for Engerix-B 10MCG is the routine immunization of all infants starting at birth. Pediatric guidelines recommend a three-dose series: the first dose at birth, the second dose at 1 to 2 months of age, and the third dose at 6 months of age. This early schedule is critical because infants who contract Hepatitis B have an extremely high risk of developing chronic, lifelong infections that can silently damage the liver over decades.

Catch-Up Vaccination for Unvaccinated Children

Physicians recommend Engerix-B 10MCG for children and adolescents up to 19 years of age who did not receive the vaccine series during infancy. Catch-up vaccination is vital to protect older children as they enter school and social environments where horizontal transmission through close contact, minor cuts, or shared personal items can occur. Completing the series ensures robust immunity before potential exposure risks increase in adolescence.

Infants Born to HBsAg-Positive Mothers

When a mother is identified as Hepatitis B surface antigen (HBsAg) positive, her newborn faces an immediate risk of perinatal transmission during delivery. In such clinical scenarios, the Engerix-B 10MCG vaccine must be administered within 12 hours of birth, concurrently with Hepatitis B Immune Globulin (HBIG) at a separate injection site. This combination provides immediate passive immunity alongside active antibody production, reducing transmission risk by over 90%.

Children with Chronic Illnesses or Immunosuppression

Children suffering from chronic medical conditions, such as chronic kidney disease, those undergoing hemodialysis, or patients with bleeding disorders like Thalassemia who require frequent blood transfusions, are at a significantly higher risk of bloodborne pathogen exposure. Pediatricians proactively prescribe the Engerix-B vaccine series to these vulnerable patient populations to prevent healthcare-associated HBV transmission.

Household and Close Contacts of HBV Carriers

If a family member or household contact is diagnosed with chronic Hepatitis B, all unvaccinated children in the household must undergo immediate immunization with Engerix-B 10MCG. Horizontal transmission within households is a well-documented route of infection, occurring through contact with saliva, open wounds, or shared household items. Vaccination provides a protective barrier, preventing the spread of the virus within the family unit.

What Does Engerix-B 10MCG (Hep B Child) Prevent?

The Engerix-B 10MCG pediatric vaccine is a highly effective preventive intervention designed to stimulate active immunity and protect against a spectrum of clinical complications associated with the Hepatitis B virus. The primary clinical outcomes and protective mechanisms achieved through this vaccination include:

• Prevention of Acute Hepatitis B Infection: Protects children from symptomatic acute illness characterized by jaundice, dark urine, extreme fatigue, abdominal pain, and hepatic tenderness.
• Prevention of Chronic Carrier State: Drastically reduces the likelihood of a child becoming a chronic carrier of HBV, which is the main reservoir for ongoing viral transmission.
• Prevention of Childhood Cirrhosis: Protects the liver parenchyma from chronic inflammation and progressive fibrotic scarring that can lead to early-onset liver failure.
• Prevention of Hepatocellular Carcinoma: Acts as the world’s first anti-cancer vaccine by preventing chronic HBV infection, which is a primary oncogenic driver of liver cancer.
• Induction of Protective Anti-HBs Antibodies: Stimulates the immune system to achieve protective antibody titers equal to or greater than 10 mIU/mL, the established clinical threshold for long-term immunity.
• Prevention of Fulminant Hepatic Failure: Protects against the rare but life-threatening complication of acute liver failure, which carries a high mortality rate in pediatric patients.
• Prevention of Hepatitis D (Delta Virus) Co-infection: Because the Hepatitis D virus requires the outer envelope of HBV to replicate, immunizing against Hepatitis B effectively prevents Hepatitis D infection.
• Establishment of Immunological Memory: Induces long-lasting memory B and T lymphocytes that rapidly reactivate antibody production upon future viral exposure, even if circulating antibody levels decline over time.
• Reduction of Vertical Transmission: Prevents mother-to-child transmission during childbirth when administered as an immediate post-exposure prophylaxis.
• Prevention of Horizontal Transmission: Limits the spread of the virus in daycare centers, schools, and playgrounds through minor cuts, abrasions, or contact with body fluids.
• Protection During Medical and Dental Procedures: Safeguards children undergoing surgical interventions, dental treatments, or emergency medical care where exposure to blood is possible.
• Protection for Thalassemia and Hemophilia Patients: Provides essential protection for children who receive frequent blood products and clotting factors.
• Prevention of HBV-Associated Membranous Nephropathy: Prevents immune-complex-mediated kidney disease, a known extrahepatic complication of chronic Hepatitis B in children.
• Maintenance of Herd Immunity: Contributes to the reduction of the overall viral load within the community, protecting unvaccinated or immunocompromised individuals who cannot mount an adequate immune response.
• Safe Co-administration Compatibility: Integrates seamlessly with other routine childhood vaccines, including DTaP, IPV, Hib, MMR, and Varicella, without compromising immunogenicity or safety.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the administration of the Engerix-B 10MCG vaccine is documented immediately to ensure a seamless and verifiable immunization record for your child. Upon successful administration of the vaccine, the healthcare professional issues an official, physical vaccination card detailing the vaccine name, manufacturer, batch or lot number, date of administration, and the due date for subsequent doses. This physical card serves as an essential medical document for school admissions, international travel, and pediatric consultations.

In addition to the physical card, Chughtai Lab leverages its advanced digital healthcare infrastructure to provide instant access to your child’s immunization records. The vaccination details are uploaded in real-time to the secure Chughtai Lab online portal and the Chughtai Lab mobile application. Parents can log in using their registered patient credentials to view, download, or print the digital immunization certificate at any time. This digital record-keeping system eliminates the risk of losing vital vaccination history and ensures that pediatricians can verify your child’s immunization status instantly during routine check-ups or emergency medical evaluations.

Engerix-B 10MCG (Hep B Child) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-HBs Antibody Titer	Titer levels >= 10 mIU/mL, indicating protective immunity against Hepatitis B.	Titer levels < 10 mIU/mL, indicating non-response or insufficient protective immunity.
Injection Site Reaction	Mild, transient erythema, swelling, or localized tenderness resolving within 24 to 48 hours.	Severe localized pain, persistent swelling, sterile abscess, or localized tissue necrosis.
Systemic Temperature	Apyrexia or mild, self-limiting low-grade fever (under 38.5°C) resolving within 1 to 2 days.	High-grade fever (above 39°C) or prolonged febrile state requiring clinical evaluation.
Pediatric Behavior	Normal activity levels, mild temporary irritability, or transient drowsiness.	Persistent, inconsolable crying lasting more than 3 hours, extreme lethargy, or seizures.
Allergic Response	No signs of systemic hypersensitivity or immediate allergic reactions.	Anaphylaxis, generalized urticaria, angioedema, or bronchospasm (extremely rare).
Cold Chain Integrity	Vaccine stored and transported continuously between 2°C and 8°C.	Exposure to freezing temperatures (below 0°C) or excessive heat, denaturing the antigen.
Administration Route	Strictly intramuscular injection in the anterolateral thigh (infants) or deltoid (older children).	Accidental subcutaneous or intradermal injection, which may reduce the vaccine’s immunogenicity.
Immunological Memory	Robust activation of memory B and T lymphocytes for long-term protection.	Failure to establish immunological memory due to underlying primary or secondary immunodeficiency.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Engerix-B 10MCG (Hep B Child)?

• Strict Cold Chain Management: Chughtai Lab maintains an uninterrupted cold chain system from procurement to administration, ensuring the Engerix-B vaccine remains highly potent and effective.
• Qualified Pediatric Nursing Staff: Our clinical staff are specially trained in pediatric vaccination techniques, ensuring a gentle, quick, and comfortable experience for your child.
• Sterile and Safe Environment: We adhere to rigorous international infection control and sterilization standards to eliminate any risk of cross-contamination.
• Nationwide Network: With vaccination services available across Pakistan, including Lahore, Karachi, and Islamabad, parents can easily access care close to home.
• Digital Immunization Records: Access your child’s complete vaccination history and certificates anytime via the secure Chughtai Lab mobile app and online portal.
• Home Vaccination Services: For added convenience, Chughtai Lab offers professional home vaccination services, bringing qualified healthcare staff to your doorstep.
• Trusted Diagnostic Excellence: With over four decades of healthcare service in Pakistan, Chughtai Lab is a name synonymous with accuracy, trust, and quality.
• Patient-Focused Care: We prioritize patient comfort and safety, providing a welcoming environment for children and comprehensive guidance for parents.